

# The one-of-a-kind protection of Nobivac<sup>®</sup> vaccines against leptospirosis in dogs

NOBIVAC<sup>®</sup> LEPTO<sub>4</sub> AND NOBIVAC EDGE<sup>®</sup> LEPTO<sub>4</sub> VACCINES HAVE BEEN SHOWN TO BE EFFECTIVE AGAINST DISEASE, MORTALITY,<sup>1</sup> AND URINARY SHEDDING.<sup>2</sup>

Merck Animal Health is committed to the science of healthier animals. Our researchers conducted the studies described here to evaluate the protection offered by Nobivac<sup>®</sup> vaccines against leptospirosis in dogs.





# **Prevents mortality** from this potentially fatal disease.<sup>1</sup>

Virtually all dogs are at risk of contracting leptospirosis through urinary shedding from animal carriers. Nobivac<sup>®</sup> Lepto<sub>4</sub>, Nobivac<sup>®</sup> Canine 1-DAPPv + L<sub>4</sub>, Nobivac EDGE<sup>®</sup> Lepto<sub>4</sub>, and Nobivac EDGE<sup>®</sup> DAPPv + L<sub>4</sub> all offer comprehensive and unique solutions for protecting dogs against this serious disease.

### **STUDY DESIGN 1**

Groups of 8-week-old beagles were vaccinated at day 0 and boosted at day 21 with either Nobivac<sup>®</sup> Lepto₄ (≥20 dogs) or placebo (≥9 dogs). In each study, both groups were subsequently challenged with 1 of 4 virulent *Leptospira* serovars.<sup>1</sup>



#### Prevented mortality caused by 4 virulent Leptospira serovars

Nobivac<sup>®</sup> Lepto<sub>4</sub> was effective in preventing mortality in 100% of dogs exposed to severe challenge with 4 *Leptospira* serovars while 40%–70% of the dogs in the control group died or required euthanasia.

## **Prevents clinical signs** while stopping urinary shedding.<sup>2</sup>

### **STUDY DESIGN 2**

Four separate studies were conducted. In each study<sup>2</sup>:

- 23 to 24 7- to 8-week-old dogs were vaccinated twice, 3 weeks apart, with Nobivac<sup>®</sup> Canine 1-DAPPv + L<sub>4</sub>—a vaccine containing distemper, adenovirus type 2, parainfluenza, parvovirus, L. canicola, L. icterohaemorrhagiae, L. pomona, and L. grippotyphosa
- 12 dogs were vaccinated with placebo

Vaccinates and control dogs were challenged 2 to 3 weeks after the second vaccination with 1 of 4 virulent *Leptospira* serovars. Urine samples were collected over a 35-day period and blood samples were collected over a 10-day period post challenge. All samples were evaluated for the presence of leptospiruria or leptospiremia.

Nobivac<sup>®</sup> Lepto<sub>4</sub> and Nobivac EDGE<sup>®</sup> Lepto<sub>4</sub> vaccines protect against all 4 virulent serovars in accordance with AAHA guidelines.<sup>3</sup>



### Featuring VacciPure<sup>™</sup> filtration for a higher level of vaccine quality



INE ADENOVIRUST

Cume Distemera

4-SERONAR LEPTOSPHOS

CANINE PARTONNELS

Discover more vaccine options available in 1-mL, 0.5-mL, and combination formulations to fit your vaccination protocols.<sup>5-8</sup>

VacciPure<sup>™</sup> filtration technology

Nobivac<sup>®</sup> Lepto

Nobivac<sup>®</sup> Canine 1-DAPPv + L<sub>4</sub>

Nobivac EDGE<sup>®</sup> DAPPv + L<sub>4</sub>

Nobivac EDGE<sup>®</sup> Lepto

#### VACCINATE WITH PEACE OF MIND. VACCINATE WITH NOBIVAC<sup>®</sup> LEPTO<sub>4</sub>.

To learn more, contact your Merck Animal Health sales representative or your distributor representative.

Customer Service: 1-800-521-5767 (Monday-Friday, 9:00AM-6:00PM EST)

Technical Services: 1-800-224-5318 (Monday-Friday, 8:30AM-7:00PM EST)



References: 1. LaFleur RL, Dant JC, Wasmoen TL. Prevention of disease and mortality in vaccinated dogs following experimental challenge with virulent leptospira. J Vet Int Med. 2011;25:747. 2. LaFleur RL, Dant JC, Wasmoen TL, et al. Prevention of leptospiremia and leptospiruria following vaccination with a DAPPv + 4-way Leptospira combination vaccine. Presented at: Proceedings of the ISCAID Symposium; October 16–19, 2016; Bristol, UK. 3. Ford RB, Larson LJ, McClure KD, Schultz RD, Welborn LV. 2017 AAHA canine vaccination guidelines. AAHA website. Available at: https://www.aaha.org/globalassets/02-guidelines/canine-vaccination/vaccination\_recommendation\_for\_general\_practice\_table.pdf. Accessed September 25, 2020. 4. Data on file. Merck Animal Health. 5. Nobivac® Lepto, [product labe]]. Madison, NJ: Merck Animal Health; 2018. 6. Nobivac<sup>®</sup> Canine 1-DAPPv + L<sub>4</sub> [product label]. Madison, NJ: Merck Animal Health; 2019. 7. Nobivac EDGE<sup>®</sup> DAPPv + L<sub>4</sub> [product label]. Madison, NJ: Merck Animal Health; 2019. 8. Nobivac EDGE® Lepto, [product label]. Madison, NJ: Merck Animal Health; 2019.



Copyright © 2020 Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co., Inc. All rights reserved. US-NOV-201000004 234939